Dr. Robert F. Onder, M.D.
Allergy & Immunology (Allergy Physician)
711 Old Ballas Rd, Suite 100
Saint Louis, MO 63141
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 155
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
MO license R9H42
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Allergy and Asthma Consultants, PC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 155
- Services billed
- 10,811
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 6,649 | 116 |
| Professional service for multiple injections of allergen | 2,607 | 125 |
| Test for allergy using allergenic extract | 1,273 | 20 |
| Test for allergy using allergenic extract injected into skin | 293 | 18 |
| Injection of drug or substance under skin or into muscle | 202 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 199 | 132 |
| Test to measure rate of airflow | 93 | 67 |
| Administration and interpretation of patient-focused health risk assessment | 76 | 55 |
| Professional service for single injection of allergen | 28 | 11 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Saint Louis, MO | 85 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Saint Louis, MO | 80 |
| Fluticasone Propionate Other prescribers in Saint Louis, MO | 73 |
| Azelastine Hcl Other prescribers in Saint Louis, MO | 71 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Saint Louis, MO | 49 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Saint Louis, MO | 46 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Saint Louis, MO | 31 |
| Levocetirizine Dihydrochloride Other prescribers in Saint Louis, MO | 18 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Saint Louis, MO | 18 |
| Advair Hfa (fluticasone propion/salmeterol) Other prescribers in Saint Louis, MO | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $116 in total to this clinician.
| Pfizer Inc. | $88.86 |
|---|---|
| Amgen Inc. | $13.89 |
| AbbVie Inc. | $13.63 |
| Food and Beverage | $116 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $196,900 in research payments for these studies, mostly to the institutions running them.
- A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Sanofi US Services Inc. · Completed · NCT06102005 - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP - A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared…
AstraZeneca Pharmaceuticals LP - A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF)
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.